Generex Biotechnology Corporation
GNBTQ
Other OTC0.00
USD
- -
- -
Return %
Stock
S&P500
1Y
-99.98
26.84
3Y
-100.00
77.03
5Y
-100.00
80.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Joseph Moscato
- Full Time Employees
- 15
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 10102 USA Today Way Miramar FL United States of America 33025
- IPO Date
- Feb 6, 1998
- Website
- generex.com
- Similar Companies
- Business
- Generex Biotechnology Corporation (GNBTQ) develops and commercializes biotechnology products and technologies for the treatment of diabetes and other diseases. The company offers AE37, an HER-2/neu peptide vaccine for breast cancer immunotherapy; oral insulin formulations under the brand names Oralin, NbOral, and NbOral-SF; and Nb301, a needle-free aerosol insulin delivery system; along with immunotherapeutic vaccines and monoclonal antibodies targeting cancer and infectious diseases. Generex operates primarily in the biopharmaceutical sector, focusing on drug delivery systems and immunotherapy solutions for patients with metabolic disorders, cancer, and immune conditions, with research and development activities centered in North America and Europe. Founded in 1988 and headquartered in Toronto, Ontario, Canada, the company pursues clinical trials and regulatory approvals through subsidiaries such as Antigen Express, Inc., which specializes in T-cell vaccines. In recent developments, Generex has advanced Phase II clinical trials for its AE37 breast cancer vaccine and explored strategic partnerships for oral insulin commercialization amid ongoing delisting proceedings from OTC markets following financial restructuring efforts.